Last reviewed · How we verify

Vehicle topical ocular, eye drops

Novaliq GmbH · Phase 3 active Small molecule

Vehicle topical ocular eye drops act as a carrier for other medications, allowing them to be delivered directly to the eye.

Vehicle topical ocular eye drops act as a carrier for other medications, allowing them to be delivered directly to the eye. Used for Treatment of dry eye disease.

At a glance

Generic nameVehicle topical ocular, eye drops
Also known asVehicle
SponsorNovaliq GmbH
ModalitySmall molecule
Therapeutic areaOphthalmology
PhasePhase 3

Mechanism of action

Vehicle topical ocular eye drops are designed to improve the solubility and stability of other medications, enabling them to be administered in a more effective and targeted manner. This can enhance the bioavailability of the active ingredient and reduce systemic side effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: